| |  Online-Ressource |
|---|
| Verfasst von: | Christopoulos, Petros [VerfasserIn]  |
|---|
| | Kluck, Klaus [VerfasserIn] |
|---|
| | Kirchner, Martina [VerfasserIn] |
|---|
| | Lüders, Heike [VerfasserIn] |
|---|
| | Roeper, Julia [VerfasserIn] |
|---|
| | Falkenstern-Ge, Roger-Fei [VerfasserIn] |
|---|
| | Szewczyk, Marlen [VerfasserIn] |
|---|
| | Sticht, Florian [VerfasserIn] |
|---|
| | Saalfeld, Felix C. [VerfasserIn] |
|---|
| | Wesseler, Claas [VerfasserIn] |
|---|
| | Hackanson, Björn [VerfasserIn] |
|---|
| | Dintner, Sebastian [VerfasserIn] |
|---|
| | Faehling, Martin [VerfasserIn] |
|---|
| | Kuon, Jonas [VerfasserIn] |
|---|
| | Janning, Melanie [VerfasserIn] |
|---|
| | Kauffmann-Guerrero, Diego [VerfasserIn] |
|---|
| | Kazdal, Daniel [VerfasserIn] |
|---|
| | Kurz, Sylke [VerfasserIn] |
|---|
| | Eichhorn, Florian [VerfasserIn] |
|---|
| | Bozorgmehr, Farastuk [VerfasserIn] |
|---|
| | Shah, Rajiv [VerfasserIn] |
|---|
| | Tufman, Amanda [VerfasserIn] |
|---|
| | Wermke, Martin [VerfasserIn] |
|---|
| | Loges, Sonja [VerfasserIn] |
|---|
| | Brueckl, Wolfgang M. [VerfasserIn] |
|---|
| | Schulz, Christian [VerfasserIn] |
|---|
| | Misch, Daniel [VerfasserIn] |
|---|
| | Frost, Nikolaj [VerfasserIn] |
|---|
| | Kollmeier, Jens [VerfasserIn] |
|---|
| | Reck, Martin [VerfasserIn] |
|---|
| | Griesinger, Frank [VerfasserIn] |
|---|
| | Grohé, Christian [VerfasserIn] |
|---|
| | Hong, Jin-Liern [VerfasserIn] |
|---|
| | Lin, Huamao M. [VerfasserIn] |
|---|
| | Budczies, Jan [VerfasserIn] |
|---|
| | Stenzinger, Albrecht [VerfasserIn] |
|---|
| | Thomas, Michael [VerfasserIn] |
|---|
| Titel: | The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions |
|---|
| Verf.angabe: | Petros Christopoulos, Klaus Kluck, Martina Kirchner, Heike Lüders, Julia Roeper, Roger-Fei Falkenstern-Ge, Marlen Szewczyk, Florian Sticht, Felix C. Saalfeld, Claas Wesseler, Björn Hackanson, Sebastian Dintner, Martin Faehling, Jonas Kuon, Melanie Janning, Diego Kauffmann-Guerrero, Daniel Kazdal, Sylke Kurz, Florian Eichhorn, Farastuk Bozorgmehr, Rajiv Shah, Amanda Tufman, Martin Wermke, Sonja Loges, Wolfgang M. Brueckl, Christian Schulz, Daniel Misch, Nikolaj Frost, Jens Kollmeier, Martin Reck, Frank Griesinger, Christian Grohé, Jin-Liern Hong, Huamao M. Lin, Jan Budczies, Albrecht Stenzinger, Michael Thomas |
|---|
| E-Jahr: | 2022 |
|---|
| Jahr: | 20 May 2022 |
|---|
| Umfang: | 13 S. |
|---|
| Fussnoten: | Gesehen am 29.08.2022 |
|---|
| Titel Quelle: | Enthalten in: European journal of cancer |
|---|
| Ort Quelle: | Amsterdam [u.a.] : Elsevier, 1992 |
|---|
| Jahr Quelle: | 2022 |
|---|
| Band/Heft Quelle: | 170(2022) vom: Juli, Seite 106-118 |
|---|
| ISSN Quelle: | 1879-0852 |
|---|
| Abstract: | Background - EGFR exon20 insertions (ex20ins) are targeted by novel compounds in non-small-cell lung cancer (NSCLC). However, data about outcome under conventional therapies and the influence of molecular features are scarce. - Patients and methods - We retrospectively analysed 118 patients with evaluation of radiologic response based on RECIST v1.1. TP53 status was available for 88 cases. - Results - Platinum doublets and chemoimmunotherapy showed similar response rates (20-25%), disease control rates (80%) and median progression-free survival (mPFS, ≈7 months), which were longer compared to monochemotherapy (9%, 59%, 4.1 months), EGFR inhibitors (0%, 46%, 3.0) and PD-(L)1 inhibitors (0%, 30%, 2.1; p < 0.05). Overall survival (OS) was not dependent on the choice of first-line treatment, but related to more lines of systemic therapy (p < 0.05). TP53 mutations and brain metastases were associated with shorter PFS under platinum doublets and EGFR inhibitors (HR 3.3-6.1, p < 0.01), and shorter OS for patients receiving both treatments (p < 0.05). More tumour CD8+ and less Th1 cells were associated with longer OS independent of brain and TP53 status (p < 0.01). No difference in outcome was noted according to the ex20ins site and use of pemetrexed (vs. other cytotoxics) or bevacizumab. Long-lasting responses (>1 year) occasionally occurred under EGFR inhibitors for both ‘near-’ and ‘far-loop’ variants. - Conclusions - Platinum doublets and chemoimmunotherapy have the highest activity with ORR of 20-25% and mPFS of approximately 7 months, regardless of the cytotoxic partner, while PD-(L)1 inhibitors show limited efficacy. TP53 mutations, brain metastases and a lower tumour CD8/Th1-cell ratio are independently associated with shorter survival. |
|---|
| DOI: | doi:10.1016/j.ejca.2022.04.020 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1016/j.ejca.2022.04.020 |
|---|
| | Volltext: https://www.sciencedirect.com/science/article/pii/S0959804922002301 |
|---|
| | DOI: https://doi.org/10.1016/j.ejca.2022.04.020 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Brain metastases |
|---|
| | CD8 cells |
|---|
| | EGFR NSCLC |
|---|
| | exon 20 |
|---|
| | Immunologic tumour microenvironment |
|---|
| | mutation |
|---|
| | Overall survival |
|---|
| | Th1 cells |
|---|
| | Treatment failure |
|---|
| K10plus-PPN: | 1815306440 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
¬The¬ impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions / Christopoulos, Petros [VerfasserIn]; 20 May 2022 (Online-Ressource)
